Turku, Finland, August 20^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.

Turku, Finland, July 19^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.

AMSTERDAM 18 July 2019 - DEARhealth, a health tech spin-out from the University of California, Los Angeles (UCLA), today announced a first closing of its Series A round with Philips Health Technology Ventures, Vesalius Biocapital III and Health Innovations. DEARhealth offers Artificial Intelligence (AI)-powered health pathways for chronic care.

Munich, 04.07.2019 - The Munich based medical technology startup Mecuris GmbH won industry expert Johannes Schneider Littfeld as Chairman of the Advisory Board. The company Mecuris offers a digital workshop for the creation and individualisation of prostheses and orthoses.

Luxembourg-Strassen, June 25, 2019 – Vesalius Biocapital III ('Vesalius'), the specialist life sciences venture capital investor, announces the final close of the VBC III fund securing EUR 120 million of equity commitments.

New York, Tuesday, 16^th April 2019: SWORD Health, a tech-enabled physical therapy provider, has raised $8 million in a series A investment round led by Khosla Ventures and several other prominent angel investors. It will allow SWORD to focus on bringing its technology to more patients' homes and expand its footprint in the U.S. market.

Tuesday, 09 April 2019 – Paralympic cyclist Denise Schindler is new brand ambassador for Medtech startup Mecuris. The Paralympic cyclist and current Vice World Champion will be the face of Mecuris for the next four years.

Turku, Finland, March 7^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that it has successfully completed Phase 1a study of its lead program FOR-6219, a novel, tissue specific treatment of endometriosis.

Wednesday, 16 January 2019 – Mecuris, a commercial stage company, teams up with certified prosthetists and orthotists (CPOs) to move orthopaedic care into the digital age.

Wednesday, 5 September 2018 – Forendo Pharma today announces that it has raised an additional €4 million of funding from Vesalius Biocapital III Partners.